摘要
尽管丙-球蛋白阿尔茨海默症合作(GAP)研究的最新结果不太理想,静脉注射免疫球蛋白( IVIG)良好的耐受性和其对患者亚群的潜在好处都强调认识IVIG作用机制的重要性。 IVIG含有淀粉样蛋白抗体表明有淀粉样蛋白清除机制,然而,淀粉样蛋白免疫疗法试验的次优结果表明有额外的机制。因此,我们测试了 IVIG 是否改变堆积在患AD的3xTg小鼠模型海马CA1区内的tau蛋白神经原纤维缠结( NFT )样的表达,对三个月大的老鼠每两个星期进行静脉注射IVIG ( 10 % , 400毫克/千克)或安慰剂( 10 %BSA /生理盐水),持续三个月或六个月。处死后,从血浆中分离得到基因表达图谱,脑组织用能识别NFTs中过度磷酸化的tau蛋白的AT-180抗体处理来进行免疫组化实验。治疗后三个月CA1区神经元的体视学分析揭示AT- 180+神经元数目无明显差异,但AT- 180突触光密度与IVIG比安慰剂组显著减少了15-20 %。相比之下, AT- 180 + CA1神经元的数目在IVIG治疗六个月后对比安慰剂组减少了25- 30%。表达谱图研究表明,IVIG治疗导致基因调节神经元细胞骨架的可塑性功能和钙介导的信号转导在血浆水平相比安慰剂显著增加40-50%。此外,几个编码蛋白磷酸酶亚基的转录本在IVIG治疗的小鼠均高出40%-50%。因此,IVIG在3xTg小鼠身上降低海马NFT的病理是通过一种可能涉及维护神经可塑性和tau蛋白磷酸化的动态平衡的机制。
关键词: 阿尔茨海默症,基因芯片,海马体,免疫球蛋白,神经元纤维缠结,神经可塑性,治疗
Current Alzheimer Research
Title:Intravenous Immunoglobulin Reduces Tau Pathology and Preserves Neuroplastic Gene Expression in the 3xTg Mouse Model of Alzheimer`s Disease
Volume: 11 Issue: 7
Author(s): Scott E. Counts, Sylvia E. Perez, Bin He and Elliott J. Mufson
Affiliation:
关键词: 阿尔茨海默症,基因芯片,海马体,免疫球蛋白,神经元纤维缠结,神经可塑性,治疗
摘要: Despite recent negative results of the Gammaglobulin Alzheimer's Partnership (GAP) trial, the good tolerability to intravenous immunoglobulin (IVIG) and its potential benefit for patient subpopulations have highlighted the importance of understanding IVIG’s mechanism of action. IVIG contains antibodies to amyloid suggesting an amyloid clearance mechanism. However, the suboptimal results of the amyloid immunotherapy trials suggest an additional mechanism. Therefore, we tested whether IVIG alters the expression of tau neurofibrillary tangle (NFT)-like deposits within hippocampal CA1 neurons of the 3xTg mouse model of AD. Three-month-old mice were treated intravenously with IVIG (10%, 400 mg/kg) or placebo (10% BSA/saline) every two weeks for either three or six months. At sacrifice, plasma was isolated for gene expression profiling and brains were processed for immunohistochemistry using the AT-180 antibody, which recognizes hyperphosphorylated tau in NFTs. Stereologic analysis of CA1 neurons following three months of treatment revealed no difference in AT-180+ neuron number but a significant 15-20% decrease in AT-180 intraneuronal optical density with IVIG compared to placebo. By contrast, the number of AT-180+ CA1 neurons was reduced by 25- 30% following six months of IVIG treatment compared to placebo. Expression profiling studies showed that IVIG treatment resulted in a significant 40-50% increase in plasma levels of genes regulating neuronal cytoskeletal plasticity function and calcium-mediated signaling compared to placebo. Moreover, several transcripts encoding protein phosphatase subunits were 40-50% higher in IVIG-treated mice. Hence, IVIG reduces hippocampal NFT pathology in the 3xTg mouse through a mechanism that may involve preservation of neuronal plasticity and tau phosphorylation homeostasis.
Export Options
About this article
Cite this article as:
Counts E. Scott, Perez E. Sylvia, He Bin and Mufson J. Elliott, Intravenous Immunoglobulin Reduces Tau Pathology and Preserves Neuroplastic Gene Expression in the 3xTg Mouse Model of Alzheimer`s Disease, Current Alzheimer Research 2014; 11 (7) . https://dx.doi.org/10.2174/1567205011666140812114037
DOI https://dx.doi.org/10.2174/1567205011666140812114037 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Acamprosate: How, Where, and for Whom Does it Work? Mechanism of Action, Treatment Targets, and Individualized Therapy
Current Pharmaceutical Design A Glycemic Threshold of 90 mg/dl Promotes Early Signs of Atherosclerosis in Apparetly Healthy Overweight/Obese Subjects
Endocrine, Metabolic & Immune Disorders - Drug Targets Cannabinoids, Opioids and MDMA: Neuropsychological Interactions Related to Addiction
Current Drug Targets A Focus on Microfluidics and Nanotechnology Approaches for the Ultra Sensitive Detection of MicroRNA
MicroRNA A Novel Immunotherapy for Alzheimers Disease: Antibodies against the β-Secretase Cleavage Site of APP
Current Alzheimer Research Beam Commissioning Data Acquisition for the Iris Variable Aperture Collimator of CyberKnife VSI
Neuroscience and Biomedical Engineering (Discontinued) Weaning and Extubation in Pediatrics
Current Respiratory Medicine Reviews Integrative Physiology of Orexins and Orexin Receptors
CNS & Neurological Disorders - Drug Targets Physiological Insights Derived from Mathematical Models of Respiration
Current Respiratory Medicine Reviews Safety with Zopiclone Use: Contemporary Issues
Current Psychopharmacology Adam and Eve - The Story of Two Adolescents
Adolescent Psychiatry Functional Interactions of Tau and their Relevance for Alzheimers Disease
Current Alzheimer Research From A1 to A3 en passant Through A2A Receptors in the Hippocampus: Pharmacological Implications
CNS & Neurological Disorders - Drug Targets Synthesis, Biological Activity of Thiazolidinones Bearing Indoline Moiety and Isatin Based Hybrids
Mini-Reviews in Organic Chemistry Analysis of miRNAs Targeting 3’UTR of H2AFX Gene: a General <i>in Silico</i> Approach
MicroRNA Antagonism of Eosinophil Accumulation in Asthma
Recent Patents on Inflammation & Allergy Drug Discovery Antipsychotics Management in Addictive Disorders
Current Psychopharmacology Advances in Extracorporeal Detoxification by MARS Dialysis in Patients with Liver Failure
Current Medicinal Chemistry A Fresh Prospect of Extracellular Matrix Hydrolytic Enzymes and Their Substrates
Current Pharmaceutical Design Mass Spectrometric Analysis of F2-Isoprostanes: Markers and Mediators in Human Disease
Current Pharmaceutical Analysis